CN Patent

CN113975243A — 以高用量含有四环性化合物的制剂

Assigned to Chugai Pharmaceutical Co Ltd · Expires 2022-01-28 · 4y expired

What this patent protects

本发明涉及作为具有ALK抑制作用的物质的四环性化合物的医药组合物，特别涉及经口给药用制剂等。通过形成9‑乙基‑6,6‑二甲基‑8‑(4‑吗啉‑4‑基‑哌啶‑1‑基)‑11‑氧代‑6,11‑二氢‑5H‑苯并[b]咔唑‑3‑甲腈或其盐的颗粒，并使该颗粒与崩解剂共存从而制成组合物或制剂，从而可以实现以高用量含有上述化合物的组合物或制剂的良好的溶出性。

USPTO Abstract

本发明涉及作为具有ALK抑制作用的物质的四环性化合物的医药组合物，特别涉及经口给药用制剂等。通过形成9‑乙基‑6,6‑二甲基‑8‑(4‑吗啉‑4‑基‑哌啶‑1‑基)‑11‑氧代‑6,11‑二氢‑5H‑苯并[b]咔唑‑3‑甲腈或其盐的颗粒，并使该颗粒与崩解剂共存从而制成组合物或制剂，从而可以实现以高用量含有上述化合物的组合物或制剂的良好的溶出性。

Drugs covered by this patent

alectinib-hydrochloride (ALECTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN113975243A
Jurisdiction: CN
Classification: —
Expires: 2022-01-28
Drug substance claim: No
Drug product claim: No
Assignee: Chugai Pharmaceutical Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.